Prospective, randomised trial of the time dependent antiplatelet effects of 500 mg and 250 mg acetylsalicylic acid i. v. and 300 mg p. o. in ACS (ACUTE)

Uwe Zeymer; Thomas Hohlfeld; Jürgen vom Dahl; Raimund Erbel; Thomas Münzel; Ralf Zahn; Alexander Roitenberg; Stefanie Breitenstein; Ákos Ferenc Pap; Dietmar Trenk

doi:10.1160/TH16-08-0650

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2017; 117(03): 625-635
DOI: 10.1160/TH16-08-0650

Atherosclerosis and Ischaemic Disease

Schattauer GmbH

Prospective, randomised trial of the time dependent antiplatelet effects of 500 mg and 250 mg acetylsalicylic acid i. v. and 300 mg p. o. in ACS (ACUTE)

Uwe Zeymer

¹Klinikum Ludwigshafen und Institut für Herzinfarktforschung Ludwigshafen, Germany

,

Thomas Hohlfeld

²Universitätsklinikum Düsseldorf, Institut für Pharmakologie und Klinische Pharmakologie, Düsseldorf, Germany

,

Jürgen vom Dahl

³Kliniken Maria Hilf GmbH, Krankenhaus St. Franziskus, Klinik für Kardiologie, Mönchengladbach, Germany

,

Raimund Erbel

⁴Universitätsklinikum Essen, Klinik für Kardiologie, Essen, Germany

,

Thomas Münzel

⁵Universitätsklinikum Mainz, Zentrum für Kardiologie, Mainz, Germany

,

Ralf Zahn

¹Klinikum Ludwigshafen und Institut für Herzinfarktforschung Ludwigshafen, Germany

,

Alexander Roitenberg

⁶Bayer Vital GmbH, Leverkusen, Germany

,

Stefanie Breitenstein

⁷Bayer Pharma AG, Wuppertal, Germany

,

Ákos Ferenc Pap

⁷Bayer Pharma AG, Wuppertal, Germany

,

Dietmar Trenk

⁸Universitäts-Herzzentrum Freiburg-Bad Krozingen, Klinische Pharmakologie, Bad Krozingen, Germany

› Institutsangaben

Abstract

Summary

Little is known about the onset of action after intravenous or oral administration of acetylsalicylic acid (ASA) in patients with acute coronary syndromes (ACS). The aim of the study was to compare intravenous 250 or 500 mg acetylsalicylic acid (ASA) with oral 300 mg in ASA naïve patients with ACS concerning the onset of antiplatelet effects measured by time dependent thromboxane inhibition. A total of 270 patients with ACS < 24 hours were randomised into one of three treatment arms comprising administration of a single dose of ASA as soon as possible after admission. The primary endpoint was platelet inhibition assessed by measurement of arachidonic acid (AA)-induced platelet thromboxane release (TXB2) 5 minutes (min) after study drug administration. Both 250 mg and 500 mg ASA i. v. inhibited TXB2 formation nearly completely (geometric means: from 581.7 and 573.9 ng/ml at baseline to 3.9 and 3.1 ng/ml at 5 min, respectively) compared to 300 mg oral ASA (geometric means: from 652.0 to 223.7 ng/ml) (p-value, ANCOVA: < 0.0001). Similar results were obtained for inhibition of AA-induced platelet aggregation (Multiplate ASPItest; from means 86.41 and 85.72 U to 23.04 and 20.57 U at 5 min, respectively) compared to 300 mg oral ASA from mean 87.18 to 75.56 U (p-value, ANCOVA: <0.0001). The rate of bleedings was low and comparable between the groups. In summary, the administration of a single dose of 250 or 500 mg ASA IV compared to 300 mg orally is associated with a faster and more complete inhibition of thromboxane generation and platelet aggregation. Bleeding complications were comparable between the groups.

Supplementary Material including a list of institutions where work was performed is available online at www.thrombosis-online.com.

Keywords

Acute coronary syndrome - acetylsalicylic acid - platelet inhibition - thromboxane - intravenous

Volltext

Referenzen

References
1 Hamm CW, Bassand JP, Agewall S. et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2999-3054.
2 Yeh RW, Sidney S, Chandra M. et al. Population trends in the incidence and out-comes of acute myocardial infarction. N Engl J Med 2010; 362: 2155-2165.
3 André R, Bongard V, Elosua R. et al. International differences in acute coronary syndrome patient’s baseline characteristics, clinical management and outcomes in Western Europe: the EURHOBOP study. Hear 2014; 100: 1201-1207.
4 Steg PG, James SK, Atar D. et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569-2619.
5 Jneid H, Anderson JL, Wright RS. et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angine/Non-ST-elev-ation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2012; 126: 875-910.
6 O’Gara PT, Kushner FG, Ascheim DD. et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127: e362-e425.
7 Nagelschmitz J, Blunck M, Kraetzschmar J. et al. Pharmacokinetics and pharma-codynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers. Clin Pharmacol Adv Appl 2014; 06: 51-59.
8 nQuery Advisor 6.01® Copyright 1995–2005. Statistical Solutions Ltd.
9 Hintze J. PASS 2002. NCSS, LLC. Kaysville, Utah, USA. 2002 www.ncss.com
10 Lewis Jr. HD., Davis JW, Archibald DG. et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 1983; 309: 396-403.
11 ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988; 02: 349-360.
12 Cairns JA, Gent M, Singer J. et al. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicentre trial. N Engl J Med 1985; 313: 1369-1375.
13 The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet. 1990; 336: 827-830.
14 Antithrombotic Trialists’s Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71-86.
15 Mehta SR, Tanguay JF, Eikelboom JW. et al. CURRENT-OASIS 7 trial investigators. Double-dose versus standard-dose clopidogral and hig-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 2010; 376: 1233-1243.
16 Freimark D, Matatzky S, Leor J. et al. Timing of aspirin administration as a determinant of survival of patients with acute myocardial infarction treated with thrombolysis. Am J Cardiol 2002; 89: 381-385.
17 Abdelnoor M, Landmark K. Infarct size is reduced and the frequency of non-Q-wave myocardial infarctions is increased in patients using aspirin at the onset of symptoms. Cardiology 1999; 91: 119-126.
18 Nordt SP, Clark RF, Castillo EM. et al. Comparison of three aspirin formulations in human volunteers. West J Emerg Med 2011; 12: 381-385.
19 Schwertner HA, McGlasson D, Christopher M. et al. Effects of different aspirin formulations on platelet aggregation times and on plasma salicylate concentrations. Thromb Res 2006; 118: 529-534.
20 Say Y, Kusaka A, Imanishi K. et al. A randomised, quadruple crossover single-blind study on immediate action of chewed and unchewed low-dose acetylsalicylic acid tablets. J Pharm Sci 2011; 100: 3884-3891.
21 Benedek IH, Joshi AS, Pieniaszek HJ. et al. Variability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteers. J Clin Pharmacol 1995; 35: 1181-1186.
22 Crescente M, Di Castelnuovo A, Iacoviello L. et al. Response variability to aspirin as assessed by the platelet function analyser (PFA)-100. A systematic review. Thromb Haemost 2008; 99: 14-26.
23 Vivas D, Bernardo E, García-Rubira JC. et al. Can resistance to aspirin be reversed after an additional dose? J Thromb Thrombolysis. 2011; 32: 356-361.
24 Gengo F, Westphal ES, Rainka M. et al. Platelet response to increased aspirin dose in patients with persistent platelet aggregation while treated with aspirin 81 mg. J Clin Pharmacol. 2015 Epub ahead of print.
25 Nishiyama A, Niikawa O, Mohri H. et al. Timing of anti-platelet effect after oral aspirin administration in patients with sympathetic excitement. Circ J 2003; 67: 697-700.
26 Achenbach S, Szardien S, Zeymer U. et al. Kommentar zu den Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC) zur Diagnostik und Therapie des akuten Koronarsyndroms ohne persistierende ST-Streckenhebung. Kardiologe 2012; 06: 283-301.
27 Zeymer U, Kastrati A, Rassaf T. et al. Kommentar zu den Leitlinien der Europäischen Gesellschaft für Kardiologie zur Therapie des akuten Herzinfarktes bei Patienten mit ST-Hebung. Kardiologe 2013; 07: 410-422.
28 Zeymer U, Mochmann HC, Mark B. et al. Double-Blind, Randomised, Prospective Comparison of Loading Doses of 600 mg Clopidogrel Versus 60 mg Prasugrel in Patients With Acute ST-Segment Elevation Myocardial Infarction Scheduled for Primary Percutaneous Intervention. JACC: Cardiovascular Interventions 2014; 08: 147-154.
29 Husted SE, Kristensen SD, Vissinger H. et al. Intravenous acetylsalicylic acid - dose-related effects on platelet function and fibrinolysis in healthy males. Thromb Haemost 1992; 68: 226-229.

Zusatzmaterial

Zusatzmaterial